MEDIUMBuilt-inProduct / Revenue mix
antibacterials and other related products
“10-K Item 1A: 'a material portion of our sales and gross profits are generated by antibacterials and other related products'”
PAHC · Concentration risk · 10-K extracted
Phibro Animal Health Corporatio (PAHC) concentration risks
Updated
The most significant concentration Phibro Animal Health Corporatio discloses is antibacterials and other related products, classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Phibro Animal Health Corporatio’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH0
MEDIUM2
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMBuilt-inGeographic
Israeli and Brazilian operations
“10-K Item 1A: 'our dependence on our Israeli and Brazilian operations'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's disclosed concentration profile spans product and geographic dimensions, with both carrying a moderate-share exposure by disclosed size. On the product side, a material portion of sales and gross profits are generated by antibacterials and other related products — a moderate-share, structural concentration by disclosed size. The filing does not provide a precise percentage for this category, but characterizes it as material, indicating that competitive pressure, generic entry, or regulatory changes affecting antibacterial products could have a meaningful effect on profitability. The geographic dimension is also moderate in disclosed size: the company's dependence on Israeli and Brazilian operations represents a meaningful share of the production and commercial base. Both geographies introduce country-specific risk channels — currency fluctuation, regulatory environment, geopolitical events, and local economic conditions in Israel and Brazil — that are distinct from the U.S. domestic operating environment. The filing identifies these two international locations as specific concentration points rather than broadly characterizing international exposure, which suggests operational depth in each. Both exposures are structural in character: the antibacterial product mix reflects the company's core animal health positioning, and the Israeli and Brazilian footprints reflect where manufacturing and commercial capabilities have been developed over time. There is no disclosed customer concentration or single-supplier dependency layered on top of these exposures. On balance, the profile presents a coherent but concentrated picture anchored in a specific product category and two international geographies; antibacterial market dynamics and country conditions in Israel and Brazil are the primary variables for investors to monitor.
For the engine’s reasoning on PAHC’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - Specialty & Generic
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals, Inc. | 2 | 1 | 0 | 3 |
| AMLX | Amylyx Pharmaceuticals, Inc. | 2 | 0 | 0 | 2 |
| AMRX | Amneal Pharmaceuticals, Inc. | 1 | 1 | 0 | 2 |
| BCRX | BioCryst Pharmaceuticals, Inc. | 0 | 2 | 0 | 2 |
| PAHC● | Phibro Animal Health Corporatio | 0 | 2 | 0 | 2 |
| ALKS | Alkermes plc | 0 | 1 | 1 | 2 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.